Identification of multiple cardiac metastases from nonsmall-cell lung cancer by 18F-FDG PET/CT A case report

被引:1
|
作者
Deng, Shengming [1 ]
Zhang, Bin [1 ]
Li, Jihui [1 ]
Sang, Shibiao [1 ]
Zhang, Wei [1 ]
机构
[1] Soochow Univ, Dept Nucl Med, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China
关键词
cardiac metastasis; F-18-fluorodeoxyglucose; nonsmall-cell lung cancer; positron-emission tomography/computed tomography; POSITRON-EMISSION-TOMOGRAPHY;
D O I
10.1097/MD.0000000000012868
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Multiple cardiac metastases from nonsmall-cell lung cancer are extremely rare. Multiple cardiac metastases detected by F-18-fluorodeoxyglucose positron-emission tomography/computed tomography (F-18-FDG PET/CT) have not been previously reported. Patient concerns: A 53-year-old man was admitted to the hospital with left back pain for 1 month. Diagnoses: A contrast-enhanced computed tomography (CECT) scan showed a moderately enhancing mass with a necrotic area in the upper left lobe of the lung and a filling defect in the interventricular septum. Two-dimensional transthoracic echocardiography identified a mass attaching to the endocardial surface of interventricular septum. F-18-FDG PET/CT showed multiple intense F-18-FDG uptakes in the cardiac region. Nonsmall-cell lung cancer was confirmed by histopathologic examination of the mass in the upper left lobe of the lung. Intervention: The patient was treated with Gemcitabine chemotherapy. Outcomes: After 18 months of follow-up, the patient achieved stable disease status according to the Response Evaluation Criteria In Solid Tumors guidelines. Lessons: Our case demonstrates that F-18-FDG PET/CT is a sensitive and feasible imaging modality to diagnosis multiple cardiac metastases.
引用
收藏
页数:3
相关论文
共 50 条
  • [1] Estimation of Recurrence Risk After Normal 18F-FDG PET/CT in Nonsmall-Cell Lung Cancer
    Pak, Kyoungjune
    Kim, Seong-Jang
    Koo, Phillip J.
    Chang, Samuel
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2016, 31 (05) : 174 - 179
  • [2] 18F-FDG PET/CT for evaluation of metastases in nonsmall cell lung cancer on the efficacy of immunotherapy
    Feng, Yawen
    Wang, Peng
    Chen, Yuqi
    Dai, Wenli
    NUCLEAR MEDICINE COMMUNICATIONS, 2023, 44 (10) : 900 - 909
  • [3] 18F-FDG PET/CT for evaluation of metastases in nonsmall cell lung cancer on the efficacy of immunotherapy
    Feng, Y.
    Wang, P.
    Chen, Y.
    Dai, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S683 - S683
  • [4] 18F-FDG PET/CT features of ureteral metastases from breast cancer: a case report
    Huang, Yuanbi
    He, Huajie
    Wei, Wei
    Li, Qiguang
    Long, Xian
    Li, Yongpeng
    Chen, Rongchao
    Yi, Xianlin
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (05)
  • [5] False negative F-18FDG PET/CT in nonsmall cell lung cancer bone metastases
    An, YS
    Yoon, DK
    Lee, MH
    Joh, CW
    Yoon, SN
    CLINICAL NUCLEAR MEDICINE, 2005, 30 (03) : 203 - 204
  • [6] A Case of Massive Bone Metastases From Lung Cancer Detected Only by 18F-FDG PET/CT
    Satoh, Yoko
    Koizumi, Kiyoshi
    Nambu, Atsushi
    Araki, Tsutomu
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (08) : E411 - E414
  • [7] Essential thrombocythemia in primary lung cancer and 18F-FDG PET/CT: Case Report
    Chaushev, B.
    Nikolova, G.
    Klisarova, A.
    Bochev, P.
    Krasnaliev, I.
    Dancheva, Z.
    Iordanov, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S359 - S359
  • [8] 18F-FDG PET/CT of Lung Adenocarcinoma With Ovarian Metastases
    Garcia-Talavera, Paloma
    Colinas, Daniel
    Tamayo, Pilar
    Fra, Joaquin
    Montes, Arnold
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (05) : 397 - 398
  • [9] 18F-FDG PET/CT in Urethral Metastases From Bladder Cancer
    Beyhan, Ediz
    Koca, Sevim Baykal
    Yucetas, Ugur
    Cermik, Tevfik Fikret
    Ergul, Nurhan
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (11) : E713 - E714
  • [10] 18F-FDG PET/CT in Clear Cell Sarcoma With Multiple Bone Metastases
    Long, Tingting
    Hu, Shuo
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (06) : 566 - 568